Individualizing prophylaxis in hemophilia: a review

References

• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013;19:e1-e47
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-44
   PubMed Web of Science ®Google Scholar
• Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965;(suppl 77):3-132
   Google Scholar
• Nilsson IM, Berntorp E, Lofqvist T, et al. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32
   PubMed Web of Science ®Google Scholar
• Feldman BM, Pai M, Rivard GE, et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006;4:1228-36
   PubMed Web of Science ®Google Scholar
• Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301-4
   PubMed Web of Science ®Google Scholar
• Trusheim MR, Burgess B, Hu SX, et al. Quantifying factors for the success of stratified medicine. Nat Rev Drug Discov 2011;10:817-33
   PubMed Web of Science ®Google Scholar
• Astermark J, Petrini P, Tengborn L, et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999;105:1109-13
   PubMed Web of Science ®Google Scholar
• Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia 2001;7:99-102
   PubMed Web of Science ®Google Scholar
• Street A. Developing models of haemophilia care. Haemophilia 2012;18(Suppl 4):89-93
   PubMedGoogle Scholar
• Björkman S, Blanchette VS, Fischer K, et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost 2010;8:730-6
   PubMed Web of Science ®Google Scholar
• Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009;7:413-20
   PubMed Web of Science ®Google Scholar
• Geraghty S, Dunkley T, Harrington C, et al. Practice patterns in haemophilia A therapy – global progress towards optimal care. Haemophilia 2006;12:75-81
   PubMed Web of Science ®Google Scholar
• Gissel M, Whelihan MF, Ferris LA, et al. The influence of prophylactic factor VIII in severe haemophilia A. Haemophilia 2011;18:193-9
   PubMedGoogle Scholar
• Valentino LA. Controversies regarding the prophylactic management of adults with severe haemophilia A. Haemophilia 2009;15:5-18, quiz 9-22
   PubMed Web of Science ®Google Scholar
• Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994;236:391-9
   PubMed Web of Science ®Google Scholar
• Fischer K, Astermark J, van der Bom JG, et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002;8:753-60
   PubMed Web of Science ®Google Scholar
• Funk MB, Schmidt H, Becker S, et al. Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy. Haemophilia 2002;8:98-103
   PubMed Web of Science ®Google Scholar
• Ravanbod R, Torkaman G, Esteki A. Biotribological and biomechanical changes after experimental haemarthrosis in the rabbit knee. Haemophilia 2011;17:124-33
   PubMedGoogle Scholar
• Valentino LA, Hakobyan N, Kazarian T, et al. Experimental haemophilic synovitis: rationale and development of a murine model of human factor VIII deficiency. Haemophilia 2004;10:280-7
   PubMedGoogle Scholar
• Valentino LA, Hakobyan N, Kazarian T, et al. Prevention of haemarthrosis in a murine model of acute joint bleeding. Haemophilia 2008;15:314-19
   Google Scholar
• van den Berg WB. Lessons from animal models of arthritis over the past decade. Arthritis Res Ther 2009;11:250
   PubMedGoogle Scholar
• Roosendaal G, TeKoppele JM, Vianen ME, et al. Blood-induced joint damage: a canine in vivo study. Arthritis Rheum 1999;42:1033-9
   PubMedGoogle Scholar
• Sabatino DE, Nichols TC, Merricks E, et al. Animal models of hemophilia. Prog Mol Biol Transl Sci 2012;105:151-209
   PubMed Web of Science ®Google Scholar
• Hakobyan N, Enockson C, Cole AA, et al. Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes. Haemophilia 2008;14:804-9
   PubMedGoogle Scholar
• Acharya SS, Kaplan RNM, Macdonald D, et al. Neoangiogenesis contributes to the development of hemophilic synovitis. Blood 2011;117:2484-93
   PubMed Web of Science ®Google Scholar
• Jansen NW, Roosendaal G, Lundin B, et al. The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy. Arthritis Rheum 2009;60:290-8
   PubMed Web of Science ®Google Scholar
• Gringeri A, Ewenstein B, Reininger A. The burden of bleeding in haemophilia: is one bleed too many? Haemophilia 2014;20:459-63
   PubMed Web of Science ®Google Scholar
• Schramm W, Gringeri A, Ljung R, et al. Haemophilia care in Europe: the ESCHQoL study. Haemophilia 2012;18:729-37
   PubMedGoogle Scholar
• Kraft J, Blanchette V, Babyn P, et al. Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. J Thromb Haemost 2012;10:2494-502
   PubMed Web of Science ®Google Scholar
• Den Uijl IE, Mauser Bunschoten EP, Roosendaal G, et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia 2011;17:849-53
   PubMed Web of Science ®Google Scholar
• Berntorp E, Spotts G, Patrone L, et al. Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method. Biologics 2014;8:115-27
   PubMedGoogle Scholar
• Ahnstrom J, Berntorp E, Lindvall K, et al. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004;10:689-97
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Collins PW, Hay CR, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004;10:428-37
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Wong WY, Ewenstein BM, et al. Development of novel treatment options for patients with haemophilia. Hamostaseologie 2013;33(Suppl 1):S36-8
   PubMedGoogle Scholar
• Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012;119:3031-7
   PubMed Web of Science ®Google Scholar
• Coyle TE, Reding M, Lin JC, et al. An open-label phase I study to evaluate the pharmacokinetics and safety profile of BAY 94-9027, a PEGylated B-domain–deleted recombinant factor VIII, in previously treated patients with severe hemophilia A. Presented at: World Federation of Hemophilia World Congress; July 8-12, Paris, France; 2012
   Google Scholar
• Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-man trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013;11:670-8
   PubMed Web of Science ®Google Scholar
• Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011;118:2695-701
   PubMed Web of Science ®Google Scholar
• Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013;369:2313-23
   PubMed Web of Science ®Google Scholar
• Saulyte Trakymiene S, Clausen N, Poulsen LH, et al. Progression of haemophilic arthropathy in children: a Lithuanian - Danish comparative study. Haemophilia 2012;19:212-18
   PubMedGoogle Scholar
• Gringeri A, Lundin B, Mackensen SV, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011;9:700-10
   PubMed Web of Science ®Google Scholar
• Pollmann H, Klamroth R, Vidovic N, et al. Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study. Ann Hematol 2013;92:689-98
   PubMed Web of Science ®Google Scholar
• Ragni MV, Fogarty PJ, Josephson NC, et al. Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres. Haemophilia 2012;18:63-8
   PubMedGoogle Scholar
• Biss TT, Chan AK, Blanchette VS, et al. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia 2008;14:923-30
   PubMed Web of Science ®Google Scholar
• Hilliard P, Zourikian N, Blanchette V, et al. Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. J Thromb Haemost 2013;11:460-6
   PubMed Web of Science ®Google Scholar
• Wu R, Luke KH, Poon MC, et al. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Haemophilia 2011;17:70-4
   PubMed Web of Science ®Google Scholar
• Dodd C, Watts RG. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center. Haemophilia 2012;18:561-7
   PubMedGoogle Scholar
• Rew L, Horner SD, Brown A. Health-risk behaviors in early adolescence. Issues Compr Pediatr Nurs 2011;34:79-96
   PubMedGoogle Scholar
• Duncan N, Shapiro A, Ye X, et al. Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States. Haemophilia 2012;18:760-5
   PubMed Web of Science ®Google Scholar
• De Moerloose P, Urbancik W, Van Den Berg HM, et al. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia 2008;14:931-8
   PubMed Web of Science ®Google Scholar
• Khair K, Gibson F, Meerabeau L. The benefits of prophylaxis: views of adolescents with severe haemophilia. Haemophilia 2011;18:e286-9
   PubMedGoogle Scholar
• Broderick CR, Herbert RD, Latimer J, et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA 2012;308:1452-9
   PubMed Web of Science ®Google Scholar
• Valentino LA, Forsyth A, Witkop M, et al. Is bleeding in hemophilia really spontaneous or activity related: analysis of US patient/caregiver data from the Hemophilia Experiences, Results and Opportunities (HERO) study. Presented at: American Society of Hematology Annual Meeting. December 7-10; New Orleans, LA; 2013
   Google Scholar
• Walsh CE, Valentino LA. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia 2009;15:1014-21
   PubMed Web of Science ®Google Scholar
• Collins P, Faradji A, Morfini M, et al. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010;8:83-9
   PubMed Web of Science ®Google Scholar
• Tagliaferri A, Coppola A, Feola G, et al. Impact on healthcare costs and quality of life of secondary prophylaxis in adolescent and adult patients with severe haemophilia A: the POTTER study [abstract PA 1.13-2]. J Thromb Haemost 2013;11:321-2
   Google Scholar
• Oldenburg J, Zimmermann R, Katsarou O, et al. A diagnostic, cross-sectional evaluation of joint status using magnetic resonance imaging in patients with severe hemophilia A treated with prophylaxis versus on-demand therapy. Presented at: World Federation of Hemophilia World Congress. July 8-12, Paris, France; 2012
   Google Scholar
• Valentino LA, Rusen L, Elezovic I, et al. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia 2014;20:398-406
   PubMed Web of Science ®Google Scholar
• Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012;10:359-67
   PubMed Web of Science ®Google Scholar
• Valentino LA, Reyes CM, Ewenstein B, et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia 2014. [Epub ahead of print]
   Google Scholar
• Collins PW, Björkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe haemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2009;8:269-75
   PubMedGoogle Scholar
• Lindvall K, Astermark J, Bjorkman S, et al. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy. Haemophilia 2012;18:855-9
   PubMed Web of Science ®Google Scholar
• Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia 2014;20:607-15
   PubMed Web of Science ®Google Scholar
• Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 2012;7:24
   PubMed Web of Science ®Google Scholar